Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Michael D. Rogers, Ph.D., as chief development officer.

Rogers will be responsible for overseeing chemistry, manufacturing, toxicology and project management as well as the advancement of compounds from the Chimerix Chemical Library. He formerly served as chief development officer at Pharmasset, which was acquired by Gilead Sciences in January 2012. Prior to joining Pharmasset, Rogers held several positions in antiviral discovery and development at GlaxoSmithKline, including serving as vice president, division of viral diseases.